Cargando…

Recent advances of bispecific antibodies in solid tumors

Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific antibody (BsAb) is attracting more and more attention as a novel strategy of antitumor immunotherapy. BsAb not only offers an effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Shengnan, Li, Anping, Liu, Qian, Yuan, Xun, Xu, Hanxiao, Jiao, Dechao, Pestell, Richard G., Han, Xinwei, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607507/ https://www.ncbi.nlm.nih.gov/pubmed/28931402 http://dx.doi.org/10.1186/s13045-017-0522-z

Ejemplares similares

Recent advances and challenges of bispecific antibodies in solid tumors
por: Wu, Yuze, et al.
Publicado: (2021)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
por: Xu, Hanxiao, et al.
Publicado: (2017)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

Chimeric antigen receptor T cells: a novel therapy for solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
por: Liu, Qian, et al.
Publicado: (2018)

Correction: DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
por: Liu, Qian, et al.
Publicado: (2022)

DACH1 suppresses breast cancer as a negative regulator of CD44
por: Xu, Hanxiao, et al.
Publicado: (2017)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Tumor organoids: applications in cancer modeling and potentials in precision medicine
por: Xu, Hanxiao, et al.
Publicado: (2022)

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
por: Yi, Ming, et al.
Publicado: (2021)

The role of CD44 in epithelial–mesenchymal transition and cancer development
por: Xu, Hanxiao, et al.
Publicado: (2015)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
por: Yi, Ming, et al.
Publicado: (2022)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
por: Liguori, Luigi, et al.
Publicado: (2022)

Endogenous Dach1 in cancer
por: Wu, Kongming, et al.
Publicado: (2015)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
por: Yi, Ming, et al.
Publicado: (2019)

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy
por: Yi, Ming, et al.
Publicado: (2019)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

A NOVEL MSLN×4-1BB BISPECIFIC ANTIBODY FOR SOLID TUMOR
por: Cheng, Liansheng, et al.
Publicado: (2023)

Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma
por: Qin, Shuang, et al.
Publicado: (2020)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

CD44 as a tumor biomarker and therapeutic target
por: Xu, Hanxiao, et al.
Publicado: (2020)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
por: Antonarelli, Gabriele, et al.
Publicado: (2021)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling
por: Han, Na, et al.
Publicado: (2015)

Fully human antibody V(H) domains to generate mono and bispecific CAR to target solid tumors
por: Wang, Guanmeng, et al.
Publicado: (2021)

Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review
por: Nejadghaderi, Seyed Aria, et al.
Publicado: (2022)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

The development of bispecific antibodies and their applications in tumor immune escape
por: Zhang, Xiaolong, et al.
Publicado: (2017)

PRELIMINARY SAFETY, EFFICACY AND PHARMACOKINETICS (PK) RESULTS OF KN026 (A HER2 BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED SOLID TUMOR PATIENTS WITH HER2 EXPRESSION
por: Xu, Ting, et al.
Publicado: (2023)

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
por: Shima, Midori
Publicado: (2020)

A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
por: Sun, Zu-Jun, et al.
Publicado: (2017)

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
por: Simão, Diana C., et al.
Publicado: (2023)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
por: Luke, Jason J, et al.
Publicado: (2021)

Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity
por: Yan, Yuheng, et al.
Publicado: (2022)

Design and Production of Bispecific Antibodies
por: Wang, Qiong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dosvi386usi6rn6kdlfi501fqs